SARS-CoV-2 in immunocompromised individuals.
SARS-CoV-2 in immunocompromised individuals.
复制标题
DOI：
10.1016/j.immuni.2022.09.006
复制
发表时间：
2022-10-11
期刊：
影响因子：
32.4
通讯作者：
Vardhana, Santosha
中科院分区：
文献类型：
--
作者：
DeWolf, Susan;Laracy, Justin C.;Perales, Miguel-Angel;Kamboj, Mini;van den Brink, Marcel R. M.;Vardhana, Santosha
由于免疫缺陷限制了病毒的预防、治疗和清除，免疫功能低下的个体，特别是患有血液系统恶性肿瘤的个体，与 SARS-CoV-2 相关的发病率和死亡率的风险增加。了解因基础疾病、免疫抑制治疗或其组合而导致免疫力受损的人群的病毒感染自然史已成为 COVID-19 大流行期间的一个重要研究领域。针对这些个体的研究为了解 COVID-19 背景下抗病毒免疫反应和过度炎症的先天性和适应性免疫的各个方面提供了重要见解。本综述介绍了对 SARS-CoV-2 免疫脆弱性的不同状态的已知信息，以及如何利用这些信息来改进免疫高危人群的预防和治疗策略。 Vardhana 及其同事讨论了患有癌症和其他免疫抑制疾病的个体的离散免疫缺陷如何让我们了解免疫系统在 SARS-CoV-2 的保护和毒性中的作用。他们讨论了这些免疫缺陷如何影响疫苗接种策略对这些个体的保护作用，并提供了限制这一高危人群中与 COVID-19 相关的发病率的见解。
Immunocompromised individuals and particularly those with hematologic malignancies are at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic deficits that limit prevention, treatment, and clearance of the virus. Understanding the natural history of viral infections in people with impaired immunity due to underlying conditions, immunosuppressive therapy, or a combination thereof has emerged as a critical area of investigation during the COVID-19 pandemic. Studies focused on these individuals have provided key insights into aspects of innate and adaptive immunity underlying both the antiviral immune response and excess inflammation in the setting of COVID-19. This review presents what is known about distinct states of immunologic vulnerability to SARS-CoV-2 and how this information can be harnessed to improve prevention and treatment strategies for immunologically high-risk populations. Vardhana and colleagues discuss how discrete immunological defects in individuals with cancer and other immunosuppressive conditions have informed our understanding of the role of the immune system in protection and toxicity from SARS-CoV-2. They discuss how these immune defects affect the protective impact of vaccination strategies in these individuals and provide insight to limit COVID-19-associated morbidity in this high-risk population.
登录
查看更多内容
影响因子：
5.9
作者：
Achiron A;Mandel M;Dreyer-Alster S;Harari G;Magalashvili D;Sonis P;Dolev M;Menascu S;Flechter S;Falb R;Gurevich M
通讯作者：
Gurevich M
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
19.6
作者：
Benotmane I;Bruel T;Planas D;Fafi-Kremer S;Schwartz O;Caillard S
通讯作者：
Caillard S
COVID-19 MRNA疫苗驱动孕妇，哺乳和非怀孕妇女的差异抗体FC功能特征。
影响因子：
17.1
作者：
Atyeo, Caroline;DeRiso, Elizabeth A.;Davis, Christine;Bordt, Evan A.;De Guzman, Rose M.;Shook, Lydia L.;Yonker, Lael M.;Fasano, Alessio;Akinwunmi, Babatunde;Lauffenburger, Douglas A.;Elovitz, Michal A.;Gray, Kathryn J.;Edlow, Andrea G.;Alter, Galit
通讯作者：
Alter, Galit
影响因子：
12.7
作者：
Aranha, Clara;Patel, Vainav;Gogoi, Dimpu
通讯作者：
Gogoi, Dimpu